Compare TransMedics Group Inc (TMDX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.41 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 26.4× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Vanguard Intermediate Term Corporate Bond ETF for 62 Days on average.
| TMDX | VCIT | |
|---|---|---|
Market Cap | $2.74B | $72.20B |
Volume | 949,331 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $150.42 | $84.82 |
52-Week Low | $61.99 | $77.98 |
Typical Hold Time | 24 Days | 62 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) trades at $78.48, up 0.27% with a bearish technical signal from moving averages. The ETF offers a 4.8% yield and 5.1% yield-to-maturity with a 6-year duration, positioning it as a core fixed-income holding. Recent institutional buying includes Engineers Gate Manager's $1.27 million purchase and HB Wealth Management increasing holdings by 242.9%.
VCIT presents a compelling risk-return profile for income investors seeking corporate bond exposure with low costs. The 0.03% expense ratio provides cost efficiency versus competitors. Risks include interest rate sensitivity and corporate credit quality concerns. Technical indicators suggest near-term consolidation around $78 support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
